Literature DB >> 16876745

Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

Tengxian Liu1, Barry S Brown, Ying Wu, Charles Antzelevitch, Peter R Kowey, Gan-Xin Yan.   

Abstract

BACKGROUND: The development of preclinical models with high predictive value for the identification of drugs with a proclivity to induce Torsade de Pointes (TdP) in the clinic has long been a pressing goal of academia, industry and regulatory agencies alike. The present study provides a blinded appraisal of drugs, in an isolated arterially-perfused rabbit ventricular wedge preparation, with and without the potential to produce TdP. METHODS AND
RESULTS: Thirteen compounds were tested for their potential for TdP using the rabbit left ventricular wedges. All investigators were blinded to the names, concentrations and molecular weights of the drugs. The compounds were prepared by the study sponsor and sent to the investigator as 4 sets of 13 stock solutions with the order within each set being assigned by a random number generator. Each compound was scored semi-quantitatively for its relative potential for TdP based on its effect on ventricular repolarization measured as QT interval, dispersion of repolarization measured as T(p-e)/QT ratio and early afterdepolarizations. Disclosure of the names and concentrations after completion of the study revealed that all compounds known to be free of TdP risk received a score of less or equal to 0.25, whereas those with known TdP risk received a score ranging from 1.00 to 7.25 at concentrations less than 100X their free therapeutic plasma C(max).
CONCLUSIONS: Our study provides a blinded evaluation of the isolated arterially-perfused rabbit wedge preparation demonstrating both a high sensitivity and specificity in the assessment of 13 agents with varying propensity for causing TdP.

Entities:  

Mesh:

Year:  2006        PMID: 16876745      PMCID: PMC1955432          DOI: 10.1016/j.hrthm.2006.04.021

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  44 in total

1.  [Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome].

Authors:  E Arellano-Rodrigo; A García; L Mont; M Roqué
Journal:  Med Clin (Barc)       Date:  2001-06-23       Impact factor: 1.725

Review 2.  Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.

Authors:  Ajay Joshi; Tara Dimino; Yogesh Vohra; Changcong Cui; Gan-Xin Yan
Journal:  J Electrocardiol       Date:  2004       Impact factor: 1.438

Review 3.  Nonclinical proarrhythmia models: predicting Torsades de Pointes.

Authors:  Chris L Lawrence; Chris E Pollard; Tim G Hammond; Jean-Pierre Valentin
Journal:  J Pharmacol Toxicol Methods       Date:  2005 Jul-Aug       Impact factor: 1.950

4.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group.

Authors:  M Møller; C T Torp-Pedersen; L Køber
Journal:  Congest Heart Fail       Date:  2001 May-Jun

5.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.

Authors:  S Zhang; Z Zhou; Q Gong; J C Makielski; C T January
Journal:  Circ Res       Date:  1999-05-14       Impact factor: 17.367

6.  Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model.

Authors:  H R Lu; P Remeysen; K Somers; A Saels; F De Clerck
Journal:  J Cardiovasc Electrophysiol       Date:  2001-05

7.  Torsade de pointes due to quinidine: observations in 31 patients.

Authors:  J L Bauman; R A Bauernfeind; J V Hoff; B Strasberg; S Swiryn; K M Rosen
Journal:  Am Heart J       Date:  1984-03       Impact factor: 4.749

8.  The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.

Authors:  Anthony A Fossa; Michael J DePasquale; David L Raunig; Michael J Avery; Derek J Leishman
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

9.  Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.

Authors:  Peter Milberg; Shahram Ramtin; Gerold Mönnig; Nani Osada; Kristina Wasmer; Günter Breithardt; Wilhelm Haverkamp; Lars Eckardt
Journal:  J Cardiovasc Pharmacol       Date:  2004-09       Impact factor: 3.105

10.  Cellular basis for the electrocardiographic J wave.

Authors:  G X Yan; C Antzelevitch
Journal:  Circulation       Date:  1996-01-15       Impact factor: 29.690

View more
  40 in total

1.  Long-Term Impact of Different Immunosuppressive Drugs on QT and PR Intervals in Renal Transplant Patients.

Authors:  Baris Ikitimur; Kahraman Cosansu; Bilgehan Karadag; Huseyin Altug Cakmak; Burcak Kilickiran Avci; Emre Erturk; Nurhan Seyahi; Zeki Ongen
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-11-04       Impact factor: 1.468

2.  Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?

Authors:  Hua Rong Lu; An N Hermans; David J Gallacher
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  The 12-lead electrocardiogram and risk of sudden death: current utility and future prospects.

Authors:  Kumar Narayanan; Sumeet S Chugh
Journal:  Europace       Date:  2015-10       Impact factor: 5.214

4.  Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Authors:  G Eichenbaum; M K Pugsley; D J Gallacher; R Towart; G McIntyre; U Shukla; J M Davenport; H R Lu; J Rohrbacher; V Hillsamer
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade.

Authors:  Shaobin Jia; Jiangfan Lian; Donglin Guo; Xiaolin Xue; Chinmay Patel; Lin Yang; Zuyi Yuan; Aiqun Ma; Gan-Xin Yan
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

6.  Evaluating intramural virtual electrodes in the myocardial wedge preparation: simulations of experimental conditions.

Authors:  G Plank; A Prassl; E Hofer; N A Trayanova
Journal:  Biophys J       Date:  2007-11-09       Impact factor: 4.033

Review 7.  Principles of safety pharmacology.

Authors:  M K Pugsley; S Authier; M J Curtis
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 8.  Biomechanics of cardiac electromechanical coupling and mechanoelectric feedback.

Authors:  Emily R Pfeiffer; Jared R Tangney; Jeffrey H Omens; Andrew D McCulloch
Journal:  J Biomech Eng       Date:  2014-02       Impact factor: 2.097

9.  Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Authors:  Pamela A Haile; Linda N Casillas; Michael J Bury; John F Mehlmann; Robert Singhaus; Adam K Charnley; Terry V Hughes; Michael P DeMartino; Gren Z Wang; Joseph J Romano; Xiaoyang Dong; Nikolay V Plotnikov; Ami S Lakdawala; Maire A Convery; Bartholomew J Votta; David B Lipshutz; Biva M Desai; Barbara Swift; Carol A Capriotti; Scott B Berger; Mukesh K Mahajan; Michael A Reilly; Elizabeth J Rivera; Helen H Sun; Rakesh Nagilla; Carol LePage; Michael T Ouellette; Rachel D Totoritis; Brian T Donovan; Barry S Brown; Khuram W Chaudhary; Peter J Gough; John Bertin; Robert W Marquis
Journal:  ACS Med Chem Lett       Date:  2018-09-26       Impact factor: 4.345

10.  A phenotypic in vitro model for the main determinants of human whole heart function.

Authors:  Maria Stancescu; Peter Molnar; Christopher W McAleer; William McLamb; Christopher J Long; Carlota Oleaga; Jean-Matthieu Prot; James J Hickman
Journal:  Biomaterials       Date:  2015-05-14       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.